drugset
drugset / Trial / NCT05537142

A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment

NCT05537142 ↗

Phase 1 Completed 33 enrolled BioVersys AG Clinical Research Units Hungary · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

To investigate the pharmacokinetics (PK) of rifabutin in subjects with hepatic impairment after single intravenous (IV) infusion of BV100

Timeline

Start
2022-09-02
Primary completion
2024-07-30
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule — Intravenous

Indications

No indication recorded.